AUTHOR=Pourhassan Hoda , Agrawal Vaibhav , Pullarkat Vinod , Aldoss Ibrahim 

TITLE=Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment

JOURNAL=Frontiers in Oncology

VOLUME=Volume 13 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1237031

DOI=10.3389/fonc.2023.1237031

ISSN=2234-943X

ABSTRACT=Blinatumomab is a bispecific T-cell engager that has shown efficacy in relapsed/refractory Philadelphia chromosome (Ph) positive and negative acute lymphoblastic leukemia (ALL).Considering its favorable safety and activity in advanced ALL, blinatumomab as a targeted immunotherapy is fast gaining a frontline position in the ALL treatment paradigm. There have been multiple completed and ongoing studies showing significant promise with improved response rates and survival outcomes, and decreased treatment toxicity and the need for multi-agent chemotherapy regimens. The early use of blinatumomab has established success in Ph negative and Ph positive B-ALL, and this has extended to older adults with ALL who have historically had substantially inferior outcomes compared to their pediatric and young adult counterparts. Herein, we will review the current data describing the early use of blinatumomab in newly diagnosed adults with B-cell ALL and future directions.This mini-review focuses on current data describing the early use of blinatumomab in newly diagnosed adults with B-cell ALL and future directions of this treatment paradigm. Considering its favorable safety and activity in advanced ALL, blinatumomab is being positioned as a frontline therapy with multiple completed and ongoing studies illustrating promising results. The upfront treatment in ALL is arguably the most paramount line of defense as it will likely determine the chance of cure, and this summary aims to highlight the current schema and future potentials of blinatumomab in treatment practices.